Every one of those 1 sits in a single category, market-trends. Ocular Therapeutix, Inc. is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Each story carries 54 original sources on average, compared with 6 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Ocular Therapeutix, Inc.
Every one of those 1 sits in a single category, market-trends. Ocular Therapeutix, Inc. is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Each story carries 54 original sources on average, compared with 6 for the broader beat in this window. At 7, the average consequence score sits above the same-window beat average of 5.8. Ocular Therapeutix, Inc. appears in 1 tracked Healthcare story from February 20, 2026.
Stories tracked
1
Sources per story
54
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Ocular Therapeutix, Inc.. Shared-story counts are live from our verified record — not editorial picks.
A wave of earnings reports and clinical trial results has triggered significant volatility across the healthcare and biotech sectors. While Genmab reported a decline in full-year profits, breakthrough Phase 3 results from Compass Pathways and Ocular Therapeutix highlight a sharp divergence between clinical success and market valuation.